Hisoar Pharmaceutical's investee company begins phase II trial for HPV-related lesions

Zhejiang Hisoar Pharmaceutical Co., Ltd. announced that its investee company, Nuowei Biotechnology (Wuxi) Co., Ltd., has completed the first patient enrollment and dosing in the Phase II clinical trial for its innovative drug, NWRD08 injection. This trial is evaluating NWRD08 as the first domestic over-the-counter tumor therapeutic vaccine for HPV16 and/or HPV18 positive HSIL patients.

NWRD08 injection is a Class I biological new drug, an advanced therapeutic nucleic acid medicine designed to activate specific T-cell immunity to clear infected cells. Unlike preventative HPV vaccines, NWRD08 targets patients already infected with HPV and exhibiting related lesions, aiming to prevent disease progression and preserve the cervix. Previous Phase I results showed promising safety and efficacy, with over 80% of subjects achieving histopathological regression or HPV viral clearance.

Zhejiang Hisoar Pharmaceutical holds approximately 9.57% equity in Nuowei Biotechnology through its participation in the Guoxin Haixiang equity investment partnership. The company reminds investors that drug development involves inherent uncertainties regarding clinical trial progress, results, and future market competition, urging caution when making investment decisions.